Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

Rhea-AI Summary

Conduit Pharmaceuticals (Nasdaq: CDT) has announced a share repurchase program authorizing the buyback of up to $1,000,000 of its outstanding common stock. The company's Board of Directors initiated this program believing the current market price doesn't reflect the stock's underlying value.

The repurchase will be executed through The Benchmark Company via open market transactions or other methods compliant with SEC Rule 10b-18. The program has no fixed expiration date and can be adjusted or terminated based on market conditions, corporate liquidity, and regulatory considerations.

CEO Dr. David Tapolczay indicated the company will use existing cash reserves for potential buybacks, while maintaining focus on upcoming pipeline milestones, including preclinical data readouts and Phase II trial initiation for AZD1656.

Positive

• Board's confidence in company's undervaluation signals potential upside
• Strategic use of cash reserves for shareholder value enhancement
• Multiple pipeline milestones expected, including Phase II trial initiation

Negative

• Relatively small buyback amount of $1M limits potential market impact
• Use of cash reserves for buyback may reduce funds available for R&D and operations

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value.

Under the program, Conduit may repurchase shares from time to time through open market transactions or other methods in compliance with SEC Rule 10b-18. Purchases will be executed by The Benchmark Company, the Company's appointed broker, and will be subject to market conditions, corporate liquidity requirements, regulatory considerations, and other factors.

The share repurchase program does not obligate the Company to acquire a particular amount of common stock and the Company will use its discretion to repurchase shares. The program has no fixed expiration date and may be adjusted or terminated at any time by the Company.

“Given the current market value of our common stock we believe it is prudent to have the option to re-purchase our shares using our existing cash reserves,” said Dr. David Tapolczay, Chief Executive Officer of Conduit. “With multiple milestones anticipated across our pipeline this year, including preclinical data readouts and Phase II trial initiation for AZD1656, we believe in a balanced approach to capital allocation.”

About Conduit Pharmaceuticals

Conduit is a multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors & Media:
info@conduitpharma.com

FAQ

How much is Conduit Pharmaceuticals' (CDT) share repurchase program worth?

Conduit Pharmaceuticals has authorized a share repurchase program worth up to $1,000,000 of its outstanding common stock.

When does CDT's share buyback program expire?

The share repurchase program has no fixed expiration date and can be adjusted or terminated at any time by the company.

Who will execute the share repurchase program for Conduit Pharmaceuticals?

The Benchmark Company, Conduit's appointed broker, will execute the share repurchase program.

What upcoming milestones does CDT expect in its pipeline?

CDT anticipates preclinical data readouts and Phase II trial initiation for AZD1656 this year.

Why is Conduit Pharmaceuticals (CDT) implementing a share buyback program?

The Board believes the current market price of CDT's common stock trades at prices that do not reflect their underlying value.